(Q47788853)

5 February 2018

title

Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model (English)

1 reference

5 February 2018

Helicobacter pylori infectious disease

1 reference

0 references

1 reference

Wei-Ying Zhou

1

1 reference

5 February 2018

Yun Shi

2

1 reference

5 February 2018

Chao Wu

3

1 reference

5 February 2018

Wei-Jun Zhang

4

1 reference

5 February 2018

Xu-Hu Mao

5

1 reference

5 February 2018

Gang Guo

6

1 reference

5 February 2018

Hai-Xia Li

7

1 reference

5 February 2018

Quan-Ming Zou

8

1 reference

5 February 2018

language of work or name

English

0 references

publication date

27 May 2009

1 reference

5 February 2018

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

5 February 2018

volume

27

1 reference

5 February 2018

issue

36

1 reference

5 February 2018

page(s)

5013-5019

1 reference

5 February 2018

Helicobacter pylori and the pathogenesis of gastroduodenal inflammation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Helicobacter pylori infection and the development of gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Immune subversion by Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Use of T cell epitopes for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Epitope-based vaccines: an update on epitope identification, vaccine design and delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

A candidate vaccine against influenza virus intensively improved the immunogenicity of a neutralizing epitope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

HpaA is essential for Helicobacter pylori colonization in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Identification of H-2d restricted Th epitopes in Urease B subunit of Helicobacter pylori.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Inhibition of Helicobacter pylori adherence by a peptide derived from neuraminyl lactose binding adhesin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole cell sonicate in mice with chronic H. pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Epitope-vaccine strategy against HIV-1: today and tomorrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Developing an epitope-driven tuberculosis (TB) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Specific T cell responses to Helicobacter pylori predict successful eradication therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Therapeutic effects of molecularly designed antigen UREB138 for mice infected with Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

An ingenious design for peptide vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.05.009

1 reference

5 February 2018

1 reference

5 February 2018